Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial

Jordan Kraaijenhof; Marcel H. A. Muskiet; Lennart Tonneijck; D. Margriet Ouwens; Mark H. H. Kramer; Daniël H. Raalte; Mark M. Smits

doi:10.1111/dom.14107

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14107 ◽

2020 ◽

Vol 22 (10) ◽

pp. 1847-1856

Author(s):

Jordan Kraaijenhof ◽

Marcel H. A. Muskiet ◽

Lennart Tonneijck ◽

D. Margriet Ouwens ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Author response for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/response1 ◽

2020 ◽

Author(s):

Jordan Kraaijenhof ◽

Marcel H.A. Muskiet ◽

Lennart Tonneijck ◽

D. Margriet Ouwens ◽

Mark H.H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Author Response ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v1/review3 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v1/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v1/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Decision letter for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v1/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Decision letter for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text

Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial

PLoS ONE ◽

10.1371/journal.pone.0228004 ◽

2020 ◽

Vol 15 (1) ◽

pp. e0228004 ◽

Cited By ~ 2

Author(s):

Takeshi Onoue ◽

Motomitsu Goto ◽

Eri Wada ◽

Mariko Furukawa ◽

Takayuki Okuji ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Controlled Trial ◽

Apolipoprotein B ◽

Controlled Trial ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text